- Home
- REFI vs STRO Comparison
REFI vs STRO Comparison
Compare REFI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | STRO |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 338.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | STRO |
|---|---|---|
| Price | $11.22 | $25.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.38 |
| AVG Volume (30 Days) | 166.5K | ★ 168.4K |
| Earning Date | 03-12-2026 | 03-23-2026 |
| Dividend Yield | ★ 16.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $15.98 | N/A |
| Revenue Next Year | $1.33 | $13.45 |
| P/E Ratio | $6.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.22 | $0.52 |
| 52 Week High | $15.20 | $27.96 |
Technical Indicators
Market Signals| Indicator | REFI | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 31.35 | 63.16 |
| Support Level | N/A | $0.76 |
| Resistance Level | $12.59 | $27.96 |
| Average True Range (ATR) | 0.32 | 2.15 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 11.22 | 78.98 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.